We are live on ! Find out more
ASMB icon

Assembly Biosciences
ASMB

36 hedge funds and large institutions have $79.4M invested in Assembly Biosciences in 2016 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 12 increasing their positions, 11 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

28% more capital invested

Capital invested by funds: $61.9M → $79.4M (+$17.5M)

9% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 11

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

16% less funds holding

Funds holding: 43 → 36 (-7)

88% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 8

Holders
36
Holders Change
-7
Holders Change %
-16.28%
% of All Funds
0.96%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
1
Increased
12
Reduced
11
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
ACP
Acuta Capital Partners
California
+$571K
2
TDC
Thompson Davis & Co
Virginia
+$91.9K
3
ACA
Avoro Capital Advisors
New York
+$45.9K
4
BFA
BlackRock Fund Advisors
California
+$42.6K
5
TRCT
Tower Research Capital (TRC)
New York
+$36.3K

Top Sellers

1
Millennium Management
Millennium Management
New York
-$401K
2
PP
Paloma Partners
Connecticut
-$314K
3
CS
Credit Suisse
Switzerland
-$220K
4
DCM
Dialectic Capital Management
Connecticut
-$219K
5
PA
Perceptive Advisors
New York
-$112K
Name Holding Trade Value Shares
Change 		Change in
Stake
Bank of New York Mellon
26
Bank of New York Mellon
New York
$93K -$14.2K -184 -15%
California Public Employees Retirement System
27
California Public Employees Retirement System
California
$81K – – –
Morgan Stanley
28
Morgan Stanley
New York
$58K +$21.9K +284 +73%
TRCT
29
Tower Research Capital (TRC)
New York
$50K +$36.3K +470 +480%
PCM
30
Prelude Capital Management
New York
$43K +$32.8K +425 +567%
BA
31
BlackRock Advisors
Delaware
$19K – – –
BIM
32
BlackRock Investment Management
Delaware
$18K +$541 +7 +3%
JP Morgan Chase
33
JP Morgan Chase
New York
$17K +$7.34K +95 +98%
Bank of America
34
Bank of America
North Carolina
$7K -$26.7K -346 -80%
Group One Trading
35
Group One Trading
Illinois
$5K +$4.48K +58 New
Manulife (Manufacturers Life Insurance)
36
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$1K – – –
PP
37
Paloma Partners
Connecticut
– -$314K -4,717 Closed
DCM
38
Dialectic Capital Management
Connecticut
– -$219K -3,293 Closed
Deutsche Bank
39
Deutsche Bank
Germany
– -$91K -1,381 Closed
LP
40
LMR Partners
United Kingdom
– -$87K -1,305 Closed
PPA
41
Parametric Portfolio Associates
Washington
– -$56K -836 Closed
Barclays
42
Barclays
United Kingdom
– -$20K -298 Closed
UBS Group
43
UBS Group
Switzerland
– -$4K -66 Closed
Creative Planning
44
Creative Planning
Kansas
– -$2K -33 Closed
1
2

ASMB Hedge Fund Activity: Q3 2016 in Review

36 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Assembly Biosciences (ASMB) for Q3 2016, worth a combined $79.4M — up 28% from $61.9M a quarter earlier.

Sellers outnumbered buyers: 8 funds closed out of ASMB and 1 opened new positions — a net loss of 7 holders — while 11 trimmed existing stakes and 12 added.

The largest buyer was Acuta Capital Partners, adding an estimated $571K. The largest seller was Millennium Management, cutting an estimated $401K.

  • 36 institutional investors held Assembly Biosciences (ASMB) as of Q3 2016, down from 43 in Q2 2016.
  • Funds reported $79.4M of Assembly Biosciences stock for Q3 2016, up 28% quarter-over-quarter.
  • 1 fund opened new Assembly Biosciences positions in Q3 2016 and 8 closed out, a net change of -7 holders.
  • The largest Assembly Biosciences buyer in Q3 2016 was Acuta Capital Partners, an estimated $571K added.
  • The largest Assembly Biosciences seller in Q3 2016 was Millennium Management, an estimated $401K sold.

Based on aggregated 13F filings for Q3 2016.